Circassia Group Plc (CIR) - Financial and Strategic SWOT Analysis Review

November 2021 | 54 pages | ID: C4FE87C43A6EN
GlobalData

Abstracts

Circassia Group Plc (CIR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Circassia Group Plc (Circassia), formerly Circassia Pharmaceuticals plc, is a medical device company that develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used for asthma management. The company offers its products to asthma specialists in the US, the UK, Sweden, Germany, China and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Group Plc Key Recent Developments

Sep 16,2021: CIRCASSIA GROUP: Interim results - ended 30 June 2021
Sep 16,2021: Circassia Group Announces unaudited interim results for the six months ended 30 June 2021
Jul 13,2021: Circassia Group: First half trading update
Apr 21,2021: Circassia Group Announces Annual Report and accounts for the year ended 31 December 2020 and Notice of 2021 Annual General Meeting
Mar 24,2021: Circassia Group: Preliminary results for the year ended 31 December 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Circassia Group Plc - Key Facts
Circassia Group Plc - Key Employees
Circassia Group Plc - Key Employee Biographies
Circassia Group Plc - Major Products and Services
Circassia Group Plc - History
Circassia Group Plc - Company Statement
Circassia Group Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Circassia Group Plc - Business Description
Business Segment: Niox Segment
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EU
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
Circassia Group Plc - SWOT Analysis
SWOT Analysis - Overview
Circassia Group Plc - Strengths
Circassia Group Plc - Weaknesses
Circassia Group Plc - Opportunities
Circassia Group Plc - Threats
Circassia Group Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Circassia Group Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 16, 2021: CIRCASSIA GROUP: Interim results - ended 30 June 2021
Sep 16, 2021: Circassia Group Announces unaudited interim results for the six months ended 30 June 2021
Jul 13, 2021: Circassia Group: First half trading update
Apr 21, 2021: Circassia Group Announces Annual Report and accounts for the year ended 31 December 2020 and Notice of 2021 Annual General Meeting
Nov 13, 2020: Circassia Group: Board appointment
Nov 10, 2020: Circassia Group: Change of registered office
Sep 17, 2020: Circassia Group : Interim results for the six months ended 30 June 2020
Jun 16, 2020: Circassia Group : Preliminary results for the year ended 31 December 2019
May 01, 2020: Circassia Pharmaceuticals: Change of name effective
Feb 28, 2020: Circassia Pharmaceuticals: re Board appointment

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Circassia Group Plc, Key Facts
Circassia Group Plc, Key Employees
Circassia Group Plc, Key Employee Biographies
Circassia Group Plc, Major Products and Services
Circassia Group Plc, History
Circassia Group Plc, Subsidiaries
Circassia Group Plc, Joint Venture
Circassia Group Plc, Key Competitors
Circassia Group Plc, Ratios based on current share price
Circassia Group Plc, Annual Ratios
Circassia Group Plc, Annual Ratios (Cont...1)
Circassia Group Plc, Annual Ratios (Cont...2)
Circassia Group Plc, Interim Ratios
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Circassia Group Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Circassia Group Plc, Performance Chart (2016 - 2020)
Circassia Group Plc, Ratio Charts
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021